Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 7, 2026, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2026.”
Celldex Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Celldex Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $282 million (effective 2026-04-01).
“On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).”
Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 6, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2024.”
Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC valued at approximately $376.2 million (effective 2024-02-29).
“On February 29, 2024, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 8,520,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $47.00 per share (the “Offering”). The net proceeds to the Company from the Offering are expected to be approximately $376.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.”
Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On February 26, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.